Function of human alveolar macrophages after a 3-day course of azithromycin in healthy volunteers

Pulmonary Pharmacology and Therapeutics

Volumn 11, Issue 4, 1998, Pages 263-269

  Aubert, J D ^c   Juillerat Jeanneret, L ^d   Fioroni, P ^d   Dayer, P ^a   Plan, P A ^b   Leuenberger, P ^d  

^a Soins Intensifs et Médecine Aiguë   (Switzerland)

^b Pfizer AG   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d NONE

Author keywords

Azithromycin; Bronchoalveolar lavage; Cytokine; Macrophage

Indexed keywords

AZITHROMYCIN; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ADULT; ARTICLE; BRONCHOSCOPY; CELL LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; EOSINOPHIL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LEUKOCYTE COUNT; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION TEST; LUNG LAVAGE; LYMPHOCYTE; LYMPHOCYTE COUNT; MACROPHAGE; MALE; NEUTROPHIL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032148178     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1998.0123     Document Type: Article

References (23)

1. 1. Charles L, Segreti J. Choosing the right macrolide antibiotic - a guide to selection. Drugs 1997; 53: 349-357.
2. 2. Wildfeuer A, Laufen H, Zimmermann T. Uptake of azithromycin in various cells and its intracellular activity under in vivo conditions. Antimicrob Agents Chemother 1996; 40: 75-79.
3. 3. Foulds G et al. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 (Suppl A): 73-82.
4. 4. Vaudaux BP, Cherpillod J, Dayer P. Concentrations of azithromycin in tonsillar and/or adenoid tissue from paediatric patients. J Antimicrob Chemother 1996; 37 (Suppl C): 45-51.
5. 5. Dunn CJ, Barradell LB. Azithromycin. A review of its pharmacological properties and use as 3 day therapy in respiratory tract infections. Drugs 1996; 51: 483-505.
6. 6. Carbon C. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 1995; 23: S10-S14.
7. 7. Akiyoshi H, Honda J, Nakahara S, Tokisawa S, Tokunaga N, Ichikawa Y, Oizumi K. Mechanism of efficacy of erythromycin on diffuse panbronchiolitis: effect of erythromycin on cytokine mRNA expression in human whole blood model. J Japan Assoc Infect Dis 1994; 68: 209-216.
8. 8. Konno S, Adachi M, Asano K, Okamoto K, Takahashi T. Antiallergic activity of roxithromycin inhibition of interleukin-5 production from mouse T-lymphocytes. Life Sci 1993; 52: 25-30.
9. 9. Black PN. The use of macrolides in the treatment of asthma. Eur Respir Rev 1996; 6: 240-243.
10. 10. Kobayashi H. Airway biofilm disease: clinical manifestations and therapeutic possibilities using macrolides. J Infect Chemother 1995; 1: 1-15.
11. 11. Labro MT, El Benna J, Babin-Chevaye C. Comparison of the in vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 1989; 24: 561-572.
12. 12. Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and auto-oxidation. J Infect Dis 1989; 159: 966-973.
13. 13. Workshop and summary guidelines. Investigative use of bronchoscopy, lavage and bronchial biopsies in asthma and other airways diseases. Eur Respir J 1992; 5: 115.
14. 14. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. Azithromycin concentrations at the sites of pulmonary infections. Eur Respir J 1990; 3: 886-890.
15. 15. Sauty A, Mauel J, Philippeaux MM, Leuenberger P. Cytostatic activity of alveolar macrophages from smokers and nonsmokers: role of interleukin-1β, interleukin-6, and tumor necrosis factor-α. Am J Respir Cell Mol Biol 1994; 11: 631-637.
16. 16. Juillerat-Jeanneret L, Fioroni P, Leuenberger P. Modulation of secretion of interleukin-6 in brain-derived microvascular endothelial cells. Endothelium 1995; 3: 31-37.
17. 17. The BAL cooperative group steering committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990; 141: S169-S202.
18. 18. Moumouni H, Garaud P, Diot P, Lemarie E, Anthonioz P. Quantification of cell loss during bronchoalveolar lavage fluid processing. Am J Respir Crit Care Med 1994; 149: 636-640.
19. 19. Entzian P, Linnemann K, Schlaak M, Zabel P. Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. Am J Respir Crit Care Med 1996; 153: 1080-1086.
20. 20. Vanbambeke F, Montenez JP, Piret J, Tulkens PM, Courtoy PJ, Mingeotleclercq MP. Interactions of the macrolide azithromycin with phospholipids. Inhibition of lysosomal phospholipase A(1) activity. Eur J Pharmacol 1996; 14: 203-214.
21. 21. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997; 41: 1399-1402.
22. 22. Patel KB, Xuan D, Tessier PR, Russomano JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40: 2375-2379.
23. 23. Conte JE, Golden J, Duncan S, McKenna E, Lin E, Zurlinden E. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996; 40: 1616-1622.